Investor information

Company Overview

Atrys Health (BME:ATRY), founded in 2015, is a Spanish multinational that provides predictive, preventive, diagnostic, and precision medical treatment services. It is a pioneer in the fields of telemedicine and next-generation radiotherapy. The company has a team of more than 2,500 professionals and is present in Spain, Portugal, Switzerland, and Latin America. Atrys organises its activity around five business units: telemedicine, oncology, diagnostics, prevention, and big data. The company has been listed on the BME Growth Market (BME) since 2016 and is part of the IBEX MAB® 15 index.

LEARN MORE ABOUT US














Shareholder structure: shareholder structure as at 25 January 2022 with 61,389,673 shares in issue

  • Free Float 37.6%
  • Excelsior Times 30.5%
  • Caser Group 5.2%
  • Global Porfolio Investments 6.3%
  • Equipo Directivo 9%
  • Inveready VC 5.1%
  • Onchena S.L. 6.2%

Share information:

2017
2018
2019
2020
2021
2022
No. of shares (thousands of shares)
11.153
20.430
22.695
33.596
61.390
61.390
P. at Period end
2,15
2,80
5,00
8,90
10,15
9,50
Maximum P.
2,15
3,32
6,05
9,00
11,25
10,50
Minimum P.
1,39
1,86
2,76
3,00
8,06
9,26
Market Capitalisation (EUR thousand)
23.979
57.205
113.475
299.005
623.105
583.202
Volume traded (thousands of shares)
260
772
3.798
7.099
11.185
171
Volume traded (EUR thousand)
1.071
10.339
19.961
48.501
104.467
1.685

Figures in thousands. Pro forma data including full year impact of acquisitions carried out.

(*) Information for the 2022 financial year updated on 25 January 2022.

Analyst Reports

Banco Sabadell Analysis Report (January 2022) Target Price: EUR 12.50

SEE PDF

JB Capital Markets (July 2021): Target Price: EUR 13.0

SEE PDF

Renta4 (July 2021) Target Price: €11.50

SEE PDF

GVC Gaesco Report (April 2021) Target Price: €9.77

SEE PDF

Rating Reports

Axesor Report March 2021

SEE PDF

Axesor Report June 2020

SEE PDF

Would you like to get in touch with the Investor Relations department?

Tell us how we can help you